Single chain TNF derivatives with individually mutated receptor binding sites reveal differential stoichiometry of ligand receptor complex formation for TNFR1 and TNFR2 - PubMed (original) (raw)
Single chain TNF derivatives with individually mutated receptor binding sites reveal differential stoichiometry of ligand receptor complex formation for TNFR1 and TNFR2
Verena Boschert et al. Cell Signal. 2010 Jul.
Abstract
Most members of the tumor necrosis factor ligand family form noncovalently linked homotrimers, capable to bind up to three molecules of the respective membrane receptors. For several receptors a membrane distal homophilic interaction domain has been identified, called pre-ligand binding assembly domain. Accordingly, affinity values determined by typical equilibrium binding studies are likely to be influenced by avidity effects. Using our recently introduced covalently stabilized TNF (single chain TNF, scTNF), we have here investigated receptor-ligand binding stoichiometry in our well characterized system of TNFR-Fas chimeras. We produced scTNF derivatives with functionally deleted individual receptor binding sites, resulting in TNF mutants capable to only bind to one or two receptor molecules, rather than three. Equilibrium binding affinity studies on ice with these molecules revealed no significant changes after a single receptor binding site had been functionally deleted. In contrast, functional abrogation of two receptor binding sites showed a strong decrease in both, affinity and bioactivity on TNFR2-Fas. In contrast, TNFR1-Fas ligand binding and receptor activation was only affected after functional deletion of all three receptor binding sites. Our data demonstrate pivotal differences in ligand/receptor interactions between TNFR1-Fas and TNFR2-Fas, arguing for avidity effects important for TNF binding and downstream signaling of TNFR2, but to a lesser extent of TNFR1. These results are supported by data revealed from chemical crosslinking experiments suggesting the existence of preformed TNFR-Fas homodimers.
(c) 2010 Elsevier Inc. All rights reserved.
Similar articles
- Structure-function relationship of tumor necrosis factor (TNF) and its receptor interaction based on 3D structural analysis of a fully active TNFR1-selective TNF mutant.
Mukai Y, Shibata H, Nakamura T, Yoshioka Y, Abe Y, Nomura T, Taniai M, Ohta T, Ikemizu S, Nakagawa S, Tsunoda S, Kamada H, Yamagata Y, Tsutsumi Y. Mukai Y, et al. J Mol Biol. 2009 Jan 30;385(4):1221-9. doi: 10.1016/j.jmb.2008.11.053. Epub 2008 Dec 6. J Mol Biol. 2009. PMID: 19084540 - Generation of mouse macrophages expressing membrane-bound TNF variants with selectivity for TNFR1 or TNFR2.
Shibata H, Abe Y, Yoshioka Y, Nomura T, Sato M, Kayamuro H, Kawara T, Arita S, Furuya T, Nagano K, Yoshikawa T, Kamada H, Tsunoda S, Tsutsumi Y. Shibata H, et al. Cytokine. 2010 Apr;50(1):75-83. doi: 10.1016/j.cyto.2009.11.022. Epub 2009 Dec 31. Cytokine. 2010. PMID: 20045350 - Fine tuning of receptor-selectivity for tumor necrosis factor-α using a phage display system with one-step competitive panning.
Abe Y, Yoshikawa T, Inoue M, Nomura T, Furuya T, Yamashita T, Nagano K, Nabeshi H, Yoshioka Y, Mukai Y, Nakagawa S, Kamada H, Tsutsumi Y, Tsunoda S. Abe Y, et al. Biomaterials. 2011 Aug;32(23):5498-504. doi: 10.1016/j.biomaterials.2011.04.018. Epub 2011 May 5. Biomaterials. 2011. PMID: 21546081 - A family of ligands for the TNF receptor superfamily.
Cosman D. Cosman D. Stem Cells. 1994 Sep;12(5):440-55. doi: 10.1002/stem.5530120501. Stem Cells. 1994. PMID: 7528588 Review. - Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: an ongoing story.
Caminero A, Comabella M, Montalban X. Caminero A, et al. J Neuroimmunol. 2011 May;234(1-2):1-6. doi: 10.1016/j.jneuroim.2011.03.004. Epub 2011 Apr 7. J Neuroimmunol. 2011. PMID: 21474190 Review.
Cited by
- TNFR1 mediates heterogeneity in single-cell NF-κB activation.
Cheng CT, Hsiao JC, Hoffmann A, Tu HL. Cheng CT, et al. iScience. 2024 Mar 11;27(4):109486. doi: 10.1016/j.isci.2024.109486. eCollection 2024 Apr 19. iScience. 2024. PMID: 38551009 Free PMC article. - TNF superfamily control of tissue remodeling and fibrosis.
Steele H, Cheng J, Willicut A, Dell G, Breckenridge J, Culberson E, Ghastine A, Tardif V, Herro R. Steele H, et al. Front Immunol. 2023 Jul 3;14:1219907. doi: 10.3389/fimmu.2023.1219907. eCollection 2023. Front Immunol. 2023. PMID: 37465675 Free PMC article. Review. - Discovery of a Non-competitive TNFR1 Antagonist Affibody with Picomolar Monovalent Potency That Does Not Affect TNFR2 Function.
Vunnam N, Been M, Huber E, Paulson C, Szymonski S, Hackel BJ, Sachs JN. Vunnam N, et al. Mol Pharm. 2023 Apr 3;20(4):1884-1897. doi: 10.1021/acs.molpharmaceut.2c00385. Epub 2023 Mar 10. Mol Pharm. 2023. PMID: 36897792 Free PMC article. - TFNR2 in Ischemia-Reperfusion Injury, Rejection, and Tolerance in Transplantation.
Kouyoumdjian A, Tchervenkov J, Paraskevas S. Kouyoumdjian A, et al. Front Immunol. 2022 Jul 7;13:903913. doi: 10.3389/fimmu.2022.903913. eCollection 2022. Front Immunol. 2022. PMID: 35874723 Free PMC article. Review. - Mutations in the binding site of TNFR1 PLAD reduce homologous interactions but can enhance antagonism of wild-type TNFR1 activity.
Albogami S, Todd I, Negm O, Fairclough LC, Tighe PJ. Albogami S, et al. Immunology. 2021 Nov;164(3):637-654. doi: 10.1111/imm.13400. Epub 2021 Aug 25. Immunology. 2021. PMID: 34363702 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous